AMGEN INC — Director's Dealing 2025

Nov 22, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2025-11-20

Reporting Person: Grygiel Nancy A. (SVP & CCO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-11-20	Common Stock	M	1500	$177.46	Acquired	8725	Direct
2025-11-20	Common Stock	S	1500	$337.2625	Disposed	7225	Direct
2025-11-20	Common Stock	M	1639	$162.60	Acquired	8864	Direct
2025-11-20	Common Stock	S	1639	$337.2625	Disposed	7225	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-11-20	Nqso (Right to Buy)	$177.46	M	1500	Disposed	2028-04-27	Common Stock (1500)	Direct
2025-11-20	Nqso (Right to Buy)	$162.60	M	1639	Disposed	2027-05-01	Common Stock (1639)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	104.6847	Indirect

Footnotes

F1: The price reported is an average price. The prices ranged from $337.17 to $337.69 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2: These shares include 96 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

F3: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.